|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Time line | Plasma 25(OH)D concentration | Solid tumours | | Haematological malignancies | | Brain tumours | | OAD1 | |
|  |  | N=32 | 100% | N=26 | 100% | N=5 | 100% | N=2 | 100% |
| Baseline | Deficiency | 12 | 37.5 | 5 | 19.2 | 2 | 40.0 | 0 | 0 |
|  | Insufficiency | 10 | 31.3 | 12 | 46.2 | 0 | 0 | 0 | 0 |
|  | Sufficiency | 8 | 25.0 | 6 | 23.1 | 2 | 40.0 | 1 | 50.0 |
|  |  | N=28 | 100% | N=25 | 100% | N=7 | 100% | N=2 | 100% |
| 3 months | Deficiency | 1 | 3.6 | 5 | 20.0 | 0 | 0 | 1 | 33.3 |
|  | Insufficiency | 10 | 35.7 | 7 | 28.0 | 0 | 0 | 0 | 0 |
|  | Sufficiency | 7 | 25.0 | 9 | 36.0 | 1 | 14.3 | 0 | 0 |
|  |  | N=14 | 100% | N=15 | 100% | N=2 | 100% | N=3 | 100% |
| 6 months | Deficiency | 1 | 7.1 | 2 | 13.3 | 0 | 0 | 0 | 0 |
|  | Insufficiency | 5 | 35.7 | 1 | 6.7 | 1 | 50.0 | 0 | 0 |
|  | Sufficiency | 2 | 14.3 | 7 | 46.7 | 0 | 0 | 2 | 100 |
|  |  | N=6 | 100% | N=13 | 100% | N=3 | 100% | N=2 | 100% |
| 12 months | Deficiency | 1 | 16.7 | 2 | 15.4 | 0 | 0 | 0 | 0 |
|  | Insufficiency | 4 | 66.7 | 4 | 30.8 | 1 | 33.3 | 0 | 0 |
|  | Sufficiency | 1 | 16.7 | 3 | 23.1 | 1 | 33.3 | 2 | 100 |
|  |  | N=4 | 100% | N=12 | 100% | N=1 | 100% | N=1 | 100% |
| 18 months | Deficiency | 0 | 0 | 2 | 16.7 | 0 | 0 | 1 | 100 |
|  | Insufficiency | 2 | 50.0 | 4 | 33.3 | 0 | 0 | 0 | 0 |
|  | Sufficiency | 1 | 25.0 | 4 | 33.3 | 1 | 100 | 0 | 0 |

**Supplementary table I**. Prevalence of plasma 25(OH)D inadequacy with data stratified by diagnostic criteria

Deficiency: <25nmol/L; Insufficiency: 25-50 nmol/L; Sufficiency: 51-75µmol/L; Inadequacy (<50nmol/L) 1OAD: other associated diagnoses.